Assessment of the Glycemic Responses to Nutritional Products (v2.0)
NCT ID: NCT05308147
Last Updated: 2022-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
12 participants
INTERVENTIONAL
2022-03-17
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Glycemic Responses to Nutritional Products
NCT05179031
Glin4: Assessment of the Glycemic Responses to Nutritional Products
NCT06797349
Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus
NCT02898766
Glycemic Index in Subjects With Diabetes Mellitus Insulin Requesting
NCT02881164
Glycaemic Index Determination in Oral Nutrition Supplements
NCT06358716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 (Reference)
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
First Reference product
Dextrose (containing 25 grams of carbohydrates)
Arm 2 (Reference)
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Second Reference product
Dextrose (containing 25 grams of carbohydrates)
Arm 3 (Reference)
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Third Reference product
Dextrose (containing 25 grams of carbohydrates)
Arm 4 (Concept)
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
First Concept product
Infant Formula (containing 25 grams of carbohydrates)
Arm 5 (Concept)
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Second Concept product
Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
Arm 6 (Concept)
All subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Third Concept product
Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
First Reference product
Dextrose (containing 25 grams of carbohydrates)
Second Reference product
Dextrose (containing 25 grams of carbohydrates)
Third Reference product
Dextrose (containing 25 grams of carbohydrates)
First Concept product
Infant Formula (containing 25 grams of carbohydrates)
Second Concept product
Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
Third Concept product
Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) between 18.5 and 27 kg/m²
Exclusion Criteria
* Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
* Major trauma or surgical event within 3 months of screening.
* Known intolerance, sensitivity or allergy to test products.
* Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
* History of cancer in the prior two years, except for non-melanoma skin cancer.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nutricia Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INQUIS Clinical Research, Ltd
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INQ-2137 v2.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.